BioXcel Therapeutics (BTAI) Income from Continuing Operations (2017 - 2026)

BioXcel Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 13708000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 0.76% year-over-year to 13708000.0; the TTM figure through Mar 2026 stood at 65881000.0 (up 0.85% YoY), while the FY2025 annual figure was 66379000.0, up 16.3% from the prior year.
• Income from Continuing Operations was 13708000.0 for Q1 2026 at BioXcel Therapeutics, up from 14357000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 13708000.0 in Q1 2026 to a low of 54866000.0 in Q4 2022.
• Historically, Income from Continuing Operations has averaged 29562294.12 across 5 years, with a median of 22057000.0 in 2023.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 110.29% in 2022, then jumped 63.14% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 54866000.0 in 2022, then soared by 59.8% to 22057000.0 in 2023, then jumped by 36.82% to 13935000.0 in 2024, then declined by 3.03% to 14357000.0 in 2025, then advanced by 4.52% to 13708000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 13708000.0 (Q1 2026), 14357000.0 (Q4 2025), and 18365000.0 (Q3 2025), per Business Quant data.